RxSight, Inc. (NASDAQ:RXST) Insider Sells $142,228.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $142,228.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,938,246.48. This trade represents a 6.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total transaction of $139,500.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total transaction of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total transaction of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total transaction of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.

RxSight Trading Down 0.7 %

NASDAQ RXST opened at $46.06 on Wednesday. RxSight, Inc. has a 12 month low of $28.88 and a 12 month high of $66.54. The company’s fifty day moving average price is $49.20 and its two-hundred day moving average price is $52.57.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. M&G Plc boosted its stake in RxSight by 12.4% during the 2nd quarter. M&G Plc now owns 159,005 shares of the company’s stock valued at $9,540,000 after acquiring an additional 17,577 shares during the last quarter. Vanguard Group Inc. boosted its stake in RxSight by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after acquiring an additional 40,500 shares during the last quarter. Algert Global LLC bought a new position in RxSight during the 2nd quarter valued at $2,488,000. Bank of New York Mellon Corp boosted its stake in RxSight by 17.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company’s stock valued at $7,190,000 after acquiring an additional 17,368 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of RxSight by 17.0% in the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock worth $20,711,000 after buying an additional 60,789 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RXST shares. Oppenheimer dropped their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group initiated coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Wells Fargo & Company lowered their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Stifel Nicolaus lowered their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight currently has an average rating of “Buy” and a consensus price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.